Richard F Ambinder
Overview
Explore the profile of Richard F Ambinder including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
221
Citations
6134
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tabbara N, Zahurak M, Zahurak M, Sterling C, Sterling C, Trutzer I, et al.
Blood Adv
. 2024 Dec;
9(5):1202-1209.
PMID: 39693511
Patients with relapsed classic Hodgkin lymphomas (cHLs) receive salvage therapy with immune checkpoint inhibitors (ICIs) or chemotherapy (no-ICI). Patients responding to therapy often undergo consolidation with allogeneic blood or marrow...
2.
Vogt S, Laudin G, Zahurak M, Vaughan J, Lakha A, Pather S, et al.
Infect Agent Cancer
. 2024 Sep;
19(1):46.
PMID: 39334203
Background: Prospective data from sub-Saharan Africa suggests that treatment outcomes for people living with HIV (PWH) with Hodgkin lymphoma (HL) are similar to those without HIV. However, real-world data from...
3.
Komlodi-Pasztor E, Escarra-Senmarti M, Bazer D, Bhatnagar A, Perez Heydrich C, Messmer M, et al.
Front Immunol
. 2024 Sep;
15:1433442.
PMID: 39295862
The monoclonal antibody rituximab improves clinical outcome in the treatment of CD20-positive lymphomatous neoplasms, and it is an established drug for treatment of these cancers. Successful mRNA COVID-19 (SARS-CoV-2) vaccination...
4.
Sarathkumara Y, Xian R, Liu Z, Yu K, Chan J, Kwong Y, et al.
Int J Cancer
. 2024 Jul;
155(8):1476-1486.
PMID: 38995124
Epstein-Barr virus (EBV) is an oncogenic virus associated with various malignancies, including classical Hodgkin lymphoma (cHL). Despite its known association, the specific role of humoral immune response to EBV remains...
5.
Rubinstein P, Galvez C, Ambinder R
Curr Opin Infect Dis
. 2024 May;
37(4):254-263.
PMID: 38820072
Purpose Of Review: Summarize the latest research of both stem cell transplantation and cellular therapy and present the implications with respect to persons with HIV (PWH), hematologic malignancies, and HIV-1...
6.
Ambinder R, Xian R
Science
. 2024 Apr;
384(6693):274.
PMID: 38635698
Codiscoverer of the Epstein-Barr virus.
7.
Li M, Smith B, Lee J, Petr J, Anders N, Wiseman R, et al.
Infect Agent Cancer
. 2024 Mar;
19(1):7.
PMID: 38439055
Background: Antiviral therapies that target herpesviruses are clinically important. Nelfinavir is a protease inhibitor that targets the human immunodeficiency virus (HIV) aspartyl protease. Previous studies demonstrated that this drug could...
8.
Skoloda D, Newman M, Norman H, Ziggas J, Ambinder R
JCO Oncol Pract
. 2024 Feb;
20(5):673-677.
PMID: 38382007
Purpose: High-dose methotrexate (HDMTX) is an antineoplastic dosing strategy used to treat various cancers including primary central nervous system lymphoma. Trimethoprim-sulfamethoxazole (TMP/SMX) is commonly used for antibiotic prophylaxis against pneumonia...
9.
Rubinstein P, Moore P, Bimali M, Lee J, Rudek M, Chadburn A, et al.
Lancet Haematol
. 2023 Aug;
10(8):e624-e632.
PMID: 37532416
Background: Brentuximab vedotin in combination with doxorubicin, vinblastine, and dacarbazine (AVD) is approved in the upfront setting for advanced stage classical Hodgkin lymphoma (cHL). People living with HIV have been...
10.
Haigentz Jr M, Lee J, Chiao E, Aboulafia D, Ratner L, Ambinder R, et al.
Clin Cancer Res
. 2023 Jul;
29(24):5038-5046.
PMID: 37523145
Purpose: To evaluate the safety, pharmacokinetics, and pharmacodynamic effects of cabozantinib, a CYP3A4 substrate, in people living with human immunodeficiency virus and cancer receiving antiretrovirals (ARV). Patients And Methods: Patients...